跳到正文
原文
STAT 主站· Matthew Herper·· 12 天前AI 评分25

为何最新心脏药物失败应让我们更怀疑AI hype

STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype

AI 导读

两项研究显示,尽管有新的遗传学理解,诺华的pelacarsen和诺和诺德的IL-6抗炎药物均未降低心脏病和中风风险。这表明新技术未能加速新药开发。

正文

By Matthew Herper

Nov. 8, 2026

Senior Writer, Medicine, Editorial Director of Events

The next time someone tells you that artificial intelligence, or any other new technology, is going to cure every disease, point them to the effort to fight heart attacks and strokes, which together are the largest killer in the developed world.

Because again and again, pharmaceutical researchers have learned the same hard lesson: technologies that were supposed to speed new medicines to patients have fallen short. Two studies presented Saturday at the annual meeting of the American Heart Association are a perfect example. A new understanding of genetics was supposed to increase the odds of success – and did anything but.

One study showed that a Novartis drug, pelacarsen, had no effect on the rate of heart attacks and strokes despite lowering a substance in the blood called lp(a), which genetics said should  reduce cardiovascular risk. Another large study, from Novo Nordisk, of an anti-inflammatory targeting a protein called IL-6 also showed no benefit. 

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT 主站 · statnews.com